Double Pack - Cancer Researchers in Berlin Confirm Existence of a Second Protection System for Cells It Blocks Lymphoma Development
An enzyme, which the researchers refer to as Suv39h1, plays
an important role in mediating senescence in white blood cells (lymphocytes).
The enzyme is activated when the oncogene ras
turns on genes in lymphocytes, and prevents them from undergoing uncontrolled
cell growth and, subsequent conversion into cancer cells. Hence, lack of
Suv39h1 can pave the way for the development of a very aggressive lymphoma.
Interestingly, the availability of the apoptotic program is not disengaged by
cellular senescence. Thus the tumor can still be treated with chemotherapy that
engages apoptotic programs to kill cancerous cells.
*Oncogene-induced
senescence as an initial barrier in lymphoma development
Melanie Braig1, Soyoung Lee1,
Christoph Loddenkemper2, Cornelia Rudolph3, Antoine
H.F.M. Peters4,5, Brigitte Schlegelberger3, Harald Stein2,
Bernd Dörken1,6, Thomas Jenuwein5 &
Clemens A. Schmitt1,6
1Charité -
Universitätsmedizin Berlin/Haematology-Oncology, 13353 Berlin, Germany.
2Charité - Universitätsmedizin Berlin
/Department of Pathology, 12200 Berlin,
Germany. 3Institute
of Cell and Molecular Pathology, Hannover
MedicalSchool,
Carl-Neuberg-Strasse 1, 30625 Hannover,
Germany. 4Friedrich
Miescher Institute for Biomedical Research, 4058 Basel, Switzerland.
5Research Institute of Molecular Pathology, 1030 Vienna, Austria.
6Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany.
Prof. Dr. med. Clemens Schmitt, M.D.
Charité - Universitätsmedizin Berlin (CVK), and MDC
Augustenburger Platz 1
13353 Berlin, Germany
Tel. +49-30-450 553 687
Fax +49-30-450 553 986
Mobile +49-163-76 96 864
e-mail clemens.schmitt@charite.de
Barbara Bachtler
Press and Public Affairs
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Robert-Rössle-Straße 10
13125 Berlin
Germany
Phone.: +49 (0) 30 94 06 - 38 96
Fax: +49 (0) 30 94 06 - 38 33
e-mail: presse@mdc-berlin.de
http://www.mdc-berlin.de/en/news